Geoffrey Martha - 31 Jul 2026 Form 4 Insider Report for Medtronic plc (MDT)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
04 Aug 2026, 19:57:55 UTC
Prior SEC filing
08 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Patricia Walesiewicz, attorney-in-fact

Key filing fact

Geoffrey Martha filed Form 4 for Medtronic plc (MDT) on 04 Aug 2026.

Key facts

  • This page summarizes Geoffrey Martha's Form 4 filing for Medtronic plc (MDT).
  • 5 reported transactions and 3 derivative rows are listed below.
  • Accepted by SEC: 04 Aug 2026, 19:57.

Change

  • Previous filing in this sequence was filed on 08 Jun 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001560409 Primary reporting owner

Martha Geoffrey

Relationship
Chairman and CEO, Director
Address
710 MEDTRONIC PARKWAY, MINNEAPOLIS
Signature
/s/ Patricia Walesiewicz, attorney-in-fact
Signature date
04 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MDT transaction

Ordinary Shares

Tax liability

Transaction value
Shares
-15,810
Change %
-5.2%
Price
$85.39*
Shares after
286,333
Date
31 Jul 2026
Ownership
Direct
Footnotes
F1, F2
MDT transaction

Ordinary Shares

Award

Transaction value
Shares
+41,533
Change %
+15%
Price
$0.000000*
Shares after
327,866
Date
03 Aug 2026
Ownership
Direct
Footnotes
F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MDT transaction Derivative

Performance Share Units

Award

Transaction value
Shares
+103,831
Change %
Price
$0.000000*
Shares after
103,831
Date
03 Aug 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
103,831
Exercise price
Footnotes
F4, F5, F6
MDT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+295,002
Change %
Price
$0.000000*
Shares after
295,002
Date
03 Aug 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
295,002
Exercise price
$86.68
Footnotes
F7
MDT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+273,150
Change %
Price
$0.000000*
Shares after
273,150
Date
03 Aug 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
273,150
Exercise price
$86.68
Footnotes
F7
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

Represents shares withheld for taxes upon the vesting of restricted stock units previously reported on Table I.

Footnote F2

Includes 980 shares acquired through dividend reinvestment since the last report filed by the reporting person.

Footnote F3

Represents restricted stock units that vest 100% on the third anniversary of the date of grant.

Footnote F4

Each performance share unit represents a contingent right to receive one share of Medtronic common stock.

Footnote F5

Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029.

Footnote F6

The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 103,831 shares will be issued. If maximum performance metrics are achieved, 249,194 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares.

Footnote F7

These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .